ArticleHeart (British Cardiac Society)2026
Frequency and natural course of American College of Cardiology/American Heart Association valvular heart disease stages in the general population: results from the population-based STAAB cohort study.
Article in Heart (British Cardiac Society), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Severe tricuspid regurgitation: aetiology, patient characteristics, and treatment: a multicentre, prospective registry.ESC heart failure · 2026Observational
Corrections and comments
- AssociatedPublication
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundValvular heart disease (VHD) is described in American guidelines as a progressive disease continuum: stage A (at-risk), stage B (progressive), stage C/D (severe). We aimed to identify frequency and course of VHD stages as well as determinants of VHD progression in the general population.
methodsThe STAAB cohort study (Characteristics and Course of Heart Failure STAges A/B and Determinants of Progression) recruited a prestratified, population-based sample of residents (30-79 years) from Würzburg, Germany, without self-reported heart failure. Participants underwent baseline transthoracic echocardiography (2013-2017) with follow-up after 3 years (2017-2021). VHD progression was defined as an increase in stage or valve intervention.
resultsOf 4943 participants (mean age 55 years, 53% women) VHD stages were: 24% no VHD, 54% stage A, 21% stage B and 0.3% stage C/D. Prevalence of VHD increased with advancing age. Among 3833 participants who were followed for a median of 34 months, 10% in stage A and 1.3% in stage B progressed. Progression rates were highest in participants aged 60-69 and 70-79 years, at rates of 15% and 25% for stage A and 1.6% and 2.6% for stage B, respectively. In multivariable age-adjusted models, elevated E/e' predicted progression from stage A, while elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) predicted progression from stage B. Continuous analysis of aortic stenosis progression showed associations with older age, higher body mass index, diabetes and baseline peak velocity.
conclusionIn a large community cohort, VHD was common, especially at older ages, and about 11% of individuals progressed within 3 years. Echocardiographic indices (E/e') and the biomarker NT-proBNP emerged as stage-specific predictors, supporting their potential role, along with age and metabolic factors, in identifying individuals at higher risk for progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.